{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:29:23Z","timestamp":1773779363939,"version":"3.50.1"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioorg.2025.109430","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T07:16:52Z","timestamp":1766992612000},"page":"109430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Current landscape and recent developments of PI3K\/AKT\/mTOR targeted inhibitors for breast carcinoma"],"prefix":"10.1016","volume":"170","author":[{"given":"Neha","family":"Rana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Deval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hridayanand","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Monika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"114","key":"10.1016\/j.bioorg.2025.109430_bb0005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2016.01.035","article-title":"Synthesis and biological evaluation of novel 2,3-dihydrochromeno[3,4-d]imidazol-4(1H)-one derivatives as potent anticancer cell proliferation and migration agents","volume":"114","author":"Han","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0010","first-page":"8","article-title":"Preparation and in vitro anticancer activity evaluation of some coumarin derivatives","volume":"10","author":"Imran","year":"2019","journal-title":"Pharmacophore"},{"key":"10.1016\/j.bioorg.2025.109430_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.109430_bb0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jff.2015.11.018","article-title":"Hua, H, coumarins from the roots of Angelica Dahurica with antioxidant and antiproliferative activities","volume":"20","author":"Bai","year":"2016","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.bioorg.2025.109430_bb0025","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.109430_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.bioorg.2025.109430_bb0035","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.109430_bb0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canep.2012.02.007","article-title":"The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality","volume":"36","author":"Youlden","year":"2012","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109430_bb0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bioorg.2025.109430_bb0055","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/MTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0060","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/MTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109430_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of MTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.109430_bb0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109430_bb0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"J, PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109430_bb0080","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1634\/theoncologist.2010-0402","article-title":"Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer","volume":"16","author":"Hernandez-Aya","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2025.109430_bb0085","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109430_bb0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109430_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2019.02.002","article-title":"PIK3CA in cancer: the past 30 years","volume":"59","author":"Arafeh","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0105","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.7150\/thno.35561","article-title":"FKBP4 connects MTORC2 and PI3K to activate the PDK1\/Akt-dependent cell proliferation signaling in breast cancer","volume":"9","author":"Mang\u00e9","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2025.109430_bb0110","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1016\/j.yexcr.2010.07.008","article-title":"Phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic","volume":"316","author":"Thoresen","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature12360","article-title":"Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate","volume":"499","author":"Posor","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109430_bb0120","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2017.09.002","article-title":"Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2\u03b1 scaffolding function","volume":"32","author":"Gulluni","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.109430_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0883-2897(88)90090-6","article-title":"99mTc bone scanning agents\u2014IV. Chemical characterization of 99mTc(Sn)-pyrophosphate complexes","volume":"15","author":"Kroesbergen","year":"1988","journal-title":"Int. J. Radiat. Appl. Instrum. Part B. Nucl. Med. Biol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tcb.2019.01.001","article-title":"Class II PI3K functions in cell biology and disease","volume":"29","author":"Gulluni","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0135","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1038\/onc.2017.295","article-title":"VPS34 stimulation of P62 phosphorylation for cancer progression","volume":"36","author":"Jiang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.109430_bb0140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13058-015-0656-2","article-title":"Dual inhibition of type I and type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers","volume":"17","author":"Young","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010964","article-title":"The role of phosphatidylinositol 3-kinase catalytic subunit type 3 in the pathogenesis of human cancer","volume":"22","author":"Chu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109430_bb0150","doi-asserted-by":"crossref","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","article-title":"Efficacy of PI3K inhibitors in advanced breast cancer","volume":"30","author":"Verret","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","article-title":"Distinct functions of AKT isoforms in breast cancer: a comprehensive review","volume":"17","author":"Hinz","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2025.109430_bb0160","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ijc.24831","article-title":"PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality","volume":"126","author":"L\u00f3pez-Knowles","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"2012","key":"10.1016\/j.bioorg.2025.109430_bb0165","first-page":"91","article-title":"FDA drug approvals","volume":"11","author":"Mullard","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109430_bb0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/MTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109430_bb0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/biomedicines11010109","article-title":"Targeting PI3K\/AKT\/MTOR pathway in breast cancer: from biology to clinical challenges","volume":"11","author":"Cerma","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2025.109430_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000443404","article-title":"Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents","volume":"25","author":"Cragg","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.bioorg.2025.109430_bb0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jat.2941","article-title":"Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K\/Akt signaling pathway","volume":"34","author":"Yang","year":"2014","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0190","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.pharep.2017.04.008","article-title":"Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K\/AKT and telomerase","volume":"69","author":"Moradzadeh","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bioorg.2025.109430_bb0195","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1142\/S0192415X20500603","article-title":"MLL3 induced by luteolin causes apoptosis in tamoxifen-resistant breast cancer cells through H3K4 monomethylation and suppression of the PI3K\/AKT\/MTOR pathway","volume":"48","author":"Wu","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.bioorg.2025.109430_bb0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2018.01.014","article-title":"Quercetin suppresses breast cancer stem cells (CD44 + \/CD24 \u2212) by inhibiting the PI3K\/Akt\/MTOR-signaling pathway","volume":"196","author":"Li","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.109430_bb0205","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/molecules24061131","article-title":"Resveratrol inhibits the migration and metastasis of MDA-MB-231 human breast cancer by reversing TGF-\u03921-induced epithelial-mesenchymal transition","volume":"24","author":"Sun","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109430_bb0210","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-0031-1286306","article-title":"Formononetin induces cell cycle arrest of human breast cancer cells via IGF1\/PI3K\/Akt pathways in vitro and in vivo","volume":"43","author":"Chen","year":"2011","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146553","article-title":"Curcumin suppresses proliferation and migration of MDA-MB-231 breast cancer cells through autophagy-dependent Akt degradation","volume":"11","author":"Guan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.109430_bb0220","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0006-2952(02)01517-4","article-title":"M, relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase\/protein kinase B (PI3K\/PKB) pathways to induction of apoptosis by curcumin in breast cells","volume":"65","author":"Squires","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0225","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7150\/jca.47553","article-title":"Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via MiR-17-5p\/PTEN\/Akt pathway","volume":"12","author":"Bao","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.bioorg.2025.109430_bb0230","first-page":"1","article-title":"Anthricin isolated from Anthriscus Sylvestris (L.) Hoffm. inhibits the growth of breast cancer cells by inhibiting Akt\/MTOR signaling, and its apoptotic effects are enhanced by autophagy inhibition","author":"Jung","year":"2013","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"10.1016\/j.bioorg.2025.109430_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110863","article-title":"Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K\/Akt\/MTOR pathway","volume":"135","author":"Won","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0240","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.foodchem.2013.04.125","article-title":"Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells","volume":"141","author":"Do","year":"2013","journal-title":"Food Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/121458","article-title":"Modulates cell viability, invasion, and growth promoting signaling pathways in HER-2-positive breast cancer cells","author":"Sehdev","year":"2009","journal-title":"J. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules28114278","article-title":"Antitumor activity of s-triazine derivatives: a systematic review","volume":"28","author":"Dai","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109430_bb0255","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(Morpholino-1,3,5-Triazine) derivatives: potent adenosine 5\u2032-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0260","article-title":"Design, synthesis, and apoptotic antiproliferative efficacy of new quinazoline\/1,3,4-oxadiazole-2-thione derived EGFR\/HER-2 dual inhibitors with anti-breast cancer activity, RSC","volume":"16","author":"Gomaa","year":"2025","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2012.10.017","article-title":"Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors","volume":"61","author":"Mowafy","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0270","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1016\/j.bmcl.2016.08.015","article-title":"Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors","volume":"26","author":"Hei","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109430_bb0275","first-page":"595","article-title":"Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells","volume":"33","author":"Zhang","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0280","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejmech.2012.03.044","article-title":"Quinazoline\u2013tyrphostin as a new class of antitumor agents, molecular properties prediction, synthesis and biological testing","volume":"53","author":"Alafeefy","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0285","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2013.04.017","article-title":"Synthesis and antiproliferative activity of 4-substituted-piperazine-1-carbodithioate derivatives of 2,4-diaminoquinazoline","volume":"64","author":"Cao","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0290","doi-asserted-by":"crossref","first-page":"22092","DOI":"10.1039\/D4RA04371E","article-title":"Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer design, synthesis, and molecular docking","volume":"14","author":"Abdelmegeed","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109430_bb0295","doi-asserted-by":"crossref","first-page":"24781","DOI":"10.1039\/D4RA04915B","article-title":"Design, synthesis, and antiproliferative screening of new quinoline derivatives bearing a cis-vinyl triamide motif as apoptosis activators and EGFR-TK inhibitors","volume":"14","author":"Hany","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109430_bb0300","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bioorg.2018.09.011","article-title":"Unveiling novel 2-Cyclopropyl-3-Ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase\/PAR-1 antagonism and platelet aggregation valuations development of a new class of anticancer drugs with thrombolytic effects","volume":"81","author":"Thangarasu","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0305","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bioorg.2018.08.007","article-title":"Design, synthesis, crystal structures and anticancer activity of 4-substituted quinolines to target PDK1","volume":"81","author":"Vennila","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0310","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin","volume":"1","author":"Knight","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109430_bb0315","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejmech.2015.05.025","article-title":"Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K\/MTOR dual inhibitors","volume":"99","author":"Lv","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0320","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmech.2017.01.016","article-title":"Discovery of a series of N -(5-(Quinolin-6-Yl)Pyridin-3-Yl)Benzenesulfonamides as PI3K\/MTOR dual inhibitors","volume":"127","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0325","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1039\/C6RA26971K","article-title":"Identification of 3-amidoquinoline derivatives as PI3K\/MTOR dual inhibitors with potential for cancer therapy","volume":"7","author":"Zhang","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109430_bb0330","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00432-010-0847-2","article-title":"Targeting PI3K in neuroblastoma","volume":"136","author":"Spitzenberg","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0335","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejmech.2011.12.023","article-title":"Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation","volume":"48","author":"Mielcke","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0340","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejmech.2014.07.099","article-title":"Design, synthesis and biological evaluation of novel Thieno[3,2-d]pyrimidine derivatives containing Diaryl urea moiety as potent antitumor agents","volume":"85","author":"Liu","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdc.2020.100363","article-title":"Anticancer activity of newly synthesized 1,2,4-oxadiazole linked 4-Oxazolo[5,4-d]pyrimidine derivatives","volume":"27","author":"Perupogu","year":"2020","journal-title":"Chem. Data Collect."},{"key":"10.1016\/j.bioorg.2025.109430_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2022.861288","article-title":"A review on fused pyrimidine systems as EGFR inhibitors and their structure\u2013activity relationship","volume":"10","author":"Yadav","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0355","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/j.bmc.2016.06.032","article-title":"Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moiety","volume":"24","author":"Sun","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0360","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1016\/j.bmc.2014.11.003","article-title":"Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as MTOR inhibitors","volume":"22","author":"Zhu","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-26571-7","article-title":"Synthesis, molecular docking, and in-vitro studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS\/PI3K\/Akt\/JNK inhibition in breast carcinoma cells","volume":"12","author":"Salem","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109430_bb0370","doi-asserted-by":"crossref","first-page":"104063","DOI":"10.1016\/j.bioorg.2020.104063","article-title":"Design, synthesis and biological evaluation of some new 2-pyrazoline derivatives as potential anticancer agents","volume":"102","author":"Tok","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0375","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bioorg.2017.10.021","article-title":"5-Acetyl-6-Methyl-4-Aryl-3,4-dihydropyrimidin-2(1H)-ones: as potent urease inhibitors synthesis, in vitro screening, and molecular modeling study","volume":"76","author":"Shamim","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0380","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1016\/j.bmcl.2014.07.073","article-title":"Synthesis and structure\u2013activity relationships of PI3K\/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3- d ]pyrimidine derivatives","volume":"24","author":"Han","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109430_bb0385","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/cbdd.13433","article-title":"Design and synthesis of 2-phenyl benzimidazole derivatives as VEGFR \u22122 inhibitors with anti-breast cancer activity","volume":"93","author":"Mostafa","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.109430_bb0390","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1039\/c0md00072h","article-title":"Discovery of the highly potent PI3K\/MTOR dual inhibitor PF-04691502 through structure based drug design","volume":"1","author":"Cheng","year":"2010","journal-title":"Medchemcomm"},{"key":"10.1016\/j.bioorg.2025.109430_bb0395","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","article-title":"Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy","volume":"132","author":"Lissitchkov","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0400","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ejmech.2012.07.011","article-title":"Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: new anticancer agents","volume":"62","author":"Husain","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0405","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/jm00001a016","article-title":"Pyrrolo[1,2-a]benzimidazole-based quinones and iminoquinones. The role of the 3-substituent on cytotoxicity","volume":"38","author":"Schulz","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0410","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0415","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1021\/acs.jmedchem.5b01655","article-title":"D, discovery of bifunctional oncogenic target inhibitors against allosteric mitogen-activated protein kinase (MEK1) and phosphatidylinositol 3-kinase (PI3K)","volume":"59","author":"Van Dort","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0420","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1021\/jm300241b","article-title":"Below, discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3K\u03b2 inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers","volume":"55","author":"Certal","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0425","first-page":"25","article-title":"Thiazolidinediones as anti-cancer agents","volume":"6","author":"Blanquicett","year":"2008","journal-title":"Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109430_bb0430","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2014.02.027","article-title":"Bifunctional ethyl 2-amino-4-methylthiazole-5-carboxylate derivatives: synthesis and in vitro biological evaluation as antimicrobial and anticancer agents","volume":"76","author":"Rostom","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0435","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmech.2011.10.031","article-title":"3,5-disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization","volume":"47","author":"Liu","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2023.1231450","article-title":"Natural product-inspired synthesis of coumarin\u2013chalcone hybrids as potential anti-breast cancer agents","volume":"14","author":"Alhakamy","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0445","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.bioorg.2019.03.003","article-title":"Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma","volume":"87","author":"Kurt","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0450","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1021\/jm00060a020","article-title":"HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum Lanigerum, [Erratum to document cited in CA117(11):108101g]","volume":"36","author":"Kashman","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0455","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.arabjc.2017.10.001","article-title":"Synthesis and biological evaluation of novel coumarin-chalcone derivatives containing urea moiety as potential anticancer agents","volume":"13","author":"Kurt","year":"2020","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0460","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bmc.2016.12.019","article-title":"Design and synthesis of new coumarin hybrids and insight into their mode of antiproliferative action","volume":"25","author":"Elshemy","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103530","article-title":"Design, synthesis and bioactivity evaluation of coumarin-chalcone hybrids as potential anticancer agents","volume":"95","author":"Wang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0470","doi-asserted-by":"crossref","first-page":"10805","DOI":"10.1002\/slct.201902089","article-title":"Design, synthesis and pharmacological evaluation of 4-hydroxycoumarin derivatives as antiproliferative agents","volume":"4","author":"Govindaiah","year":"2019","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109430_bb0475","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsmedchemlett.8b00125","article-title":"Novel nitric oxide donors of phenylsulfonylfuroxan and 3-benzyl coumarin derivatives as potent antitumor agents","volume":"9","author":"Guo","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109430_bb0480","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00044-018-2140-x","article-title":"Design, synthesis and biological evaluation of novel furoxan-based coumarin derivatives as antitumor agents","volume":"27","author":"Zhang","year":"2018","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0485","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/acs.jmedchem.9b00622","article-title":"Discovery of novel dual poly(ADP-ribose)polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0490","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejmech.2017.02.015","article-title":"Design, synthesis, and biological evaluation of imidazo[1,2- b ]pyridazine derivatives as MTOR inhibitors","volume":"129","author":"Mao","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0495","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1016\/j.bmc.2015.08.013","article-title":"Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-Yl)benzo[d]thiazol-2-Yl)urea as anticancer agents with low toxicity","volume":"23","author":"Xie","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0500","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2012.06.013","article-title":"Substituted thiazoles VI, synthesis and antitumor activity of new 2-acetamido- and 2 or 3-propanamido-thiazole analogues","volume":"54","author":"El-Messery","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0505","article-title":"The anti-breast cancer therapeutic potential of 1,2,3-triazole-containing hybrids","volume":"357","author":"Song","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.109430_bb0510","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/j.bmcl.2017.05.028","article-title":"Discovery of a novel aminopyrazine series as selective PI3K\u03b1 inhibitors","volume":"27","author":"Barlaam","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109430_bb0515","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1039\/C5MD00371G","article-title":"1,3,4-oxadiazole derivatives as potential antitumor agents: discovery, optimization and biological activity valuation","volume":"7","author":"Luo","year":"2016","journal-title":"Medchemcomm"},{"key":"10.1016\/j.bioorg.2025.109430_bb0520","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml300309h","article-title":"Discovery of the highly potent PI3K\/mTOR dual inhibitor PF-04979064 through structure-based drug design","volume":"4","author":"Cheng","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109430_bb0525","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml300309h","article-title":"Discovery of the highly potent PI3K\/MTOR dual inhibitor PF-04979064 through structure-based drug design","volume":"4","author":"Cheng","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109430_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2022.103846","article-title":"Novel pyridine and pyrimidine derivatives as promising anticancer agents: a review","volume":"15","author":"Albratty","year":"2022","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0535","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/acs.jmedchem.9b01736","article-title":"Design, synthesis, and biological evaluation of imidazo[1,2- a ]pyridine derivatives as novel PI3K\/MTOR dual inhibitors","volume":"63","author":"Yu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0540","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2022.2155638","article-title":"Design, synthesis and evaluation of 2, 6, 8-substituted imidazopyridine derivatives as potent PI3K \u03b1 inhibitors","volume":"38","author":"Chen","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109430_bb0545","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.3390\/molecules25204630","article-title":"Identification of novel thiazolo[5,4-b]pyridine derivatives as potent phosphoinositide 3-kinase inhibitors","volume":"25","author":"Xia","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109430_bb0550","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","article-title":"Clinical and biomarker results from phase I\/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0555","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0560","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA -mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109430_bb0565","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2\u2013 advanced breast cancer (BELLE-4)","volume":"28","author":"Mart\u00edn","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0570","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","article-title":"Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Krop","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0575","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"TBCRC 032 IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer","volume":"26","author":"Lehmann","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0580","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/2159-8290.CD-20-0553","article-title":"Triplet therapy with palbociclib, taselisib, and fulvestrant in PIK3CA -mutant breast cancer and doublet palbociclib and taselisib in pathway-mutant solid cancers","volume":"11","author":"Pascual","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.109430_bb0585","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1158\/1078-0432.CCR-21-3078","article-title":"Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer","volume":"28","author":"Radovich","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0590","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41416-022-02025-9","article-title":"A phase 1B open-label study of Gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer","volume":"128","author":"Curigliano","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.109430_bb0595","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0600","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PD1-11","article-title":"Abstract PD1\u201311: mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer","volume":"81","author":"Schmid","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0610","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bioorg.2025.109430_bb0620","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1128","article-title":"First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3K\u03b1 inhibitor, as a single agent in patients (Pts) with advanced solid tumors and in combination with Fulvestrant in pts with advanced breast cancer","volume":"42","author":"Saura","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0625","series-title":"A First-in-Human Study of Mutant-Selective PI3K\u03b1 Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer","year":"2021"},{"key":"10.1016\/j.bioorg.2025.109430_bb0635","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/cancers15030703","article-title":"Current state and future challenges for PI3K inhibitors in cancer therapy","volume":"15","author":"Sirico","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.109430_bb0640","doi-asserted-by":"crossref","first-page":"92","DOI":"10.33696\/cancerimmunol.6.089","article-title":"A paradoxical AKT: exploring the promise and challenges of PI3K\/AKT\/MTOR targeted therapies","volume":"6","author":"Parkman","year":"2024","journal-title":"J. Cancer Immunol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0645","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-018-0797-x","article-title":"Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges","volume":"17","author":"Butti","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109430_bb0650","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/MTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109430_bb0655","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","article-title":"Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy","volume":"6","author":"Okkenhaug","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.109430_bb0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095219","article-title":"Activation of the PI3K\/MTOR\/AKT pathway and survival in solid tumors: systematic review and meta-analysis","volume":"9","author":"Ocana","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.109430_bb0665","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/nyas.12060","article-title":"Challenges in the clinical development of PI3K inhibitors","volume":"1280","author":"Massacesi","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.109430_bb0670","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.3390\/cells11162508","article-title":"PI3K\/AKT\/MTOR-targeted therapy for breast cancer","volume":"11","author":"Zhu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109430_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116850","article-title":"Strategic advancements in targeting the PI3K\/AKT\/MTOR pathway for breast cancer therapy","volume":"236","author":"Garg","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109430_bb0680","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109430_bb0685","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"J, CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109430_bb0690","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-16-2142","article-title":"PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses","volume":"23","author":"Sai","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109430_bb0695","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.3390\/ijms22105207","article-title":"Inhibition of the PI3K\/mTOR pathway in breast cancer to enhance response to immune checkpoint inhibitors in breast cancer","volume":"22","author":"Yan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109430_bb0700","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41586-023-05940-w","article-title":"PI3K\u03b2 controls immune evasion in PTEN-deficient breast tumours","volume":"617","author":"Bergholz","year":"2023","journal-title":"Nature"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825013100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825013100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:10:25Z","timestamp":1770066625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825013100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":137,"alternative-id":["S0045206825013100"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109430","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape and recent developments of PI3K\/AKT\/mTOR targeted inhibitors for breast carcinoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109430"}}